Progesterone for women with threatened miscarriage (STOP trial): a placebo-controlled randomized clinical trial.

Study Question: In women with threatened miscarriage, does progesterone supplementation until the completion of the first trimester of pregnancy increase the probability of live birth?

Summary Answer: In women with threatened miscarriage, 400 mg vaginal progesterone nightly, from onset of bleeding until 12 weeks, did not increase live birth rates.

What Is Known Already: Limited evidence has indicated that vaginal micronized progesterone may make little or no difference to the live birth rate when compared with placebo in women with threatened miscarriage. Subgroup analysis of one recent randomized trial reported that in women with bleeding and at least one previous miscarriage, progesterone might be of benefit.

Caesarean scar ectopic pregnancy: Experience from an Australian tertiary centre.

Background: Despite the rising incidence of caesarean scar pregnancy (CSP), as yet there are no consensus or evidence-based guidelines for management.

Aims: To review diagnosis, treatment and management of all women with CSP over a 5 year period at Mater Mothers' Hospital, Brisbane, Australia.

Materials And Methods: Retrospective cohort study of CSP between 2013-2018.

Utility of βhCG monitoring in the follow-up of medical management of miscarriage.

Objective: To evaluate the percentage change in total βeta-unit human chorionic gonadotropin (βhCG) levels (%ΔβhCG) in the prediction of treatment outcomes following intravaginal misoprostol for missed miscarriage before 13 weeks.

Methods: A secondary analysis of a randomised controlled study of medical management of miscarriage was performed. Total βhCG levels were collected before misoprostol (baseline) and after a planned seven day interval (follow-up), when a transvaginal ultrasound (TVUS) reported a gestational sac as present or not.

The medical management of missed miscarriage: outcomes from a prospective, single-centre, Australian cohort.

Objective: To report the prospective outcomes of medical management of missed miscarriage before 13 weeks' gestation from an Australian cohort.

Design: Descriptive study of a cohort selected out of a randomised controlled trial.

Setting: Outpatient management at a maternity hospital between 1 May 2007 and 28 July 2010.

Can we use a lower intravaginal dose of misoprostol in the medical management of miscarriage? A randomised controlled study.

Background: The optimal dose of misoprostol to be used in the medical management of miscarriage before 13 weeks has not been resolved.

Aim: To evaluate the effectiveness and side effect profile of two different dosages of misoprostol.

Methods: A randomised controlled, equivalence study comparing 400 vs 800 μg misoprostol per vaginum (PV) on an outpatient basis.